Alzamend Neuro (ALZN) Times Interest Earned (2020 - 2026)
Alzamend Neuro's (ALZN) quarterly Times Interest Earned came in at 19139.18 in Q2 2026, down 755.35% year-over-year from 2920.47 in Q2 2025, and down 1064.38% quarter-over-quarter from 1643.72 in Q1 2026.
Powered by 
Analysis
Alzamend Neuro (ALZN) Times Interest Earned (2020 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Times Interest Earned across 7 years of filings, most recently posting 19139.18 for Q2 2026.
- In Q2 2026, Times Interest Earned fell 755.35% year-over-year to 19139.18; the TTM figure through Apr 2026 stood at 1324.5 (down 431.03% YoY), while the FY2026 annual figure was 1324.5, down 431.03% from the prior year.
- Times Interest Earned came in at 19139.18 for Q2 2026 at Alzamend Neuro, down from 1643.72 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of 80.16 in Q3 2024 to a low of 19139.18 in Q2 2026.
- Average Times Interest Earned over 5 years is 2674.82, with a median of 1078.29 recorded in 2024.
- Year-over-year, Times Interest Earned plunged 17955.54% in 2022 and jumped 95.83% in 2024.
- Over 5 years, Times Interest Earned stood at 865.78 in 2022, then gained by 22.26% to 673.1 in 2023, then soared by 42.27% to 388.57 in 2024, then climbed by 3.03% to 376.79 in 2025, then slumped by 4979.57% to 19139.18 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were 19139.18 in Q2 2026, 1643.72 in Q1 2026, and 376.79 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.08 |
| 10 | Alzamend Neuro | 5.54 Mn | 5.54 Mn | - | -19,139.18 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -19,139.18 |
| Jan 31, 2026 | -1,643.72 |
| Oct 31, 2025 | -376.79 |
| Jul 31, 2025 | -1,087.48 |
| Apr 30, 2025 | -2,237.60 |
| Jan 31, 2025 | -513.83 |
| Oct 31, 2024 | -388.57 |
| Jul 31, 2024 | -80.16 |
| Apr 30, 2024 | -580.25 |
| Jan 31, 2024 | -1,069.10 |
| Oct 31, 2023 | -673.10 |
| Jul 31, 2023 | -1,921.49 |
| Apr 30, 2023 | -6,368.03 |
| Jan 31, 2023 | -2,630.22 |
| Oct 31, 2022 | -865.78 |
| Jul 31, 2022 | -1,981.42 |
| Apr 30, 2022 | -6,433.22 |
| Jan 31, 2022 | -156.85 |
| Oct 31, 2021 | -224.07 |
| Jul 31, 2021 | -169.23 |